cefdinir NDC 68788-8115

NDC codes

FDA NDC Directory

Product NDC (as listed)68788-8115Labeler and product segments. Claims need a package NDC.

Product NDC at billing width68788-8115Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
68788-8115-1	68788811501	100 mL in 1 BOTTLE (68788-8115-1)Marketed from Mar 21, 2024
68788-8115-6	68788811506	60 mL in 1 BOTTLE (68788-8115-6)Marketed from Dec 7, 2021

How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): cefdinir
Generic name (nonproprietary): cefdinir
Active ingredients: Cefdinir — 125 mg/5mL
Dosage form: Powder, For suspension
Route: Oral
Labeler: Preferred Pharmaceuticals Inc.
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 210534
Marketing start: Dec 7, 2021
Listing expires: Dec 31, 2027
Other FDA classes: Cephalosporins (Chemical structure)
Identifiers: Product ID 68788-8115_cf33cd39-8df0-4681-8f01-c39a72e845fbSPL ID cf33cd39-8df0-4681-8f01-c39a72e845fbSPL set ID 2e384d98-642e-4841-9f62-fcea4c242f4eRxCUI 309054UNII CI0FAO63WC
Pharmacologic class: Cephalosporin Antibacterial

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.

NDC on a medical claim

N468788811501 followed by a unit qualifier and the quantity

Package 68788-8115-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Mar 24, 2026.

Indications (excerpt from the label)

INDICATIONS & USAGE To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefdinir and other antibacterial drugs, cefdinir should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefdinir for oral suspension is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated mi…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under ANDA 210534

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 210534
Product	Strength	Form · route	Labeler	Product NDC
cefdinir	Cefdinir 125 mg/5mL	Powder, For suspensionOral	A-S Medication Solutions	50090-7929
cefdinir	Cefdinir 250 mg/5mL	Powder, For suspensionOral	Ascend Laboratories, LLC	67877-548
cefdinir	Cefdinir 125 mg/5mL	Powder, For suspensionOral	Ascend Laboratories, LLC	67877-547
Cefdinir	Cefdinir 250 mg/5mL	Powder, For suspensionOral	DIRECT RX	72189-259
cefdinir	Cefdinir 250 mg/5mL	Powder, For suspensionOral	A-S Medication Solutions	50090-5811